Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $39.00.

A number of equities research analysts have recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $37.30 on Wednesday. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical has a 12-month low of $20.83 and a 12-month high of $40.95. The stock has a market cap of $1.22 billion, a P/E ratio of 31.61 and a beta of 1.06. The company has a 50-day moving average of $37.58 and a two-hundred day moving average of $32.13.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The business had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. As a group, research analysts predict that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of COLL. Pacer Advisors Inc. raised its stake in shares of Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after acquiring an additional 883,380 shares during the period. SummerHaven Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares in the last quarter. Natixis Advisors L.P. boosted its position in shares of Collegium Pharmaceutical by 152.9% in the third quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock worth $1,215,000 after buying an additional 32,865 shares during the period. Loomis Sayles & Co. L P grew its stake in shares of Collegium Pharmaceutical by 32.7% in the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after buying an additional 67,439 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after buying an additional 188,347 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.